Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy.

British Journal of Cancer
W WeichertG Kristiansen

Abstract

High activity of histone deacetylases (HDACs) causes epigenetic alterations associated with malignant cell behaviour. Consequently, HDAC inhibitors have entered late-phase clinical trials as new antineoplastic drugs. However, little is known about expression and function of specific HDAC isoforms in human tumours including prostate cancer. We investigated the expression of class I HDACs in 192 prostate carcinomas by immunohistochemistry and correlated our findings to clinicopathological parameters including follow-up data. Class I HDAC isoforms were strongly expressed in the majority of the cases (HDAC1: 69.8%, HDAC2: 74%, HDAC3: 94.8%). High rates of HDAC1 and HDAC2 expression were significantly associated with tumour dedifferentiation. Strong expression of all HDACs was accompanied by enhanced tumour cell proliferation. In addition, HDAC2 was an independent prognostic marker in our prostate cancer cohort. In conclusion, we showed that the known effects of HDACs on differentiation and proliferation of cancer cells observed in vitro can also be confirmed in vivo. The class I HDAC isoforms 1, 2 and 3 are differentially expressed in prostate cancer, which might be important for upcoming studies on HDAC inhibitors in this tumour e...Continue Reading

References

May 20, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M W KattanP T Scardino
Jan 5, 2002·International Journal of Cancer. Journal International Du Cancer·Ho Jeong KwonKyu-Won Kim
Dec 14, 2002·Biochemical and Biophysical Research Communications·You Mie LeeKyu-Won Kim
Feb 12, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Noriyuki TakaiH Phillip Koeffler
Feb 27, 2004·Biochemical and Biophysical Research Communications·Seong Hwan KimSungyoul Hong
Mar 26, 2004·The Prostate·Kalipso HalkidouCraig N Robson
Sep 25, 2004·The Prostate·Katrine Frønsdal, Fahri Saatcioglu
Jan 8, 2005·Medicinal Research Reviews·Roman A BlahetaJindrich Cinatl
Jan 20, 2005·Journal of the National Cancer Institute·Long-Cheng LiRajvir Dahiya
Feb 5, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Aurelia NoskeKai Wiechen
Mar 17, 2005·Breast Cancer Research and Treatment·Claudia A KruscheJoachim Alfer
Apr 12, 2005·Annual Review of Pharmacology and Toxicology·Daryl C DrummondChristopher C Benz
Apr 27, 2005·International Journal of Radiation Oncology, Biology, Physics·Prakash ChinnaiyanPaul M Harari
Jan 7, 2006·Nature Reviews. Cancer·Saverio Minucci, Pier Giuseppe Pelicci
Jan 24, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David Z QianRoberto Pili
Feb 18, 2006·Nature Reviews. Drug Discovery·Christine B Yoo, Peter A Jones
Mar 8, 2006·Urologic Oncology·Zhengwang ZhangJer-Tsong Hsieh
Jan 24, 2007·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun

❮ Previous
Next ❯

Citations

Mar 15, 2014·BMC Clinical Pathology·Cédric PoyetGlen Kristiansen
Dec 23, 2008·BMC Cancer·Florian R FritzscheGlen Kristiansen
Apr 23, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Junko SuzukiE Shelley Hwang
May 7, 2009·Proceedings of the National Academy of Sciences of the United States of America·Michael HaberlandEric N Olson
Mar 23, 2010·Cancer Chemotherapy and Pharmacology·Luke A WittenburgDouglas H Thamm
Dec 2, 2010·Investigational New Drugs·Enrique M Ocio, Jesús F San Miguel
Jan 5, 2011·Journal of Biomedicine & Biotechnology·Chiara V Segré, Susanna Chiocca
Apr 22, 2011·Journal of Hematology & Oncology·Xiaoxin S XuGan Wang
Jun 2, 2011·Journal of Biomedicine & Biotechnology·Hidemi Rikiishi
Jun 16, 2012·Molecular BioSystems·Jae-Kyung Myung, Marianne D Sadar
Jul 4, 2013·Cancer Chemotherapy and Pharmacology·Dana E RathkopfGeorge Wilding
Nov 13, 2013·The Journal of Pharmacology and Experimental Therapeutics·Durgadevi RavillahChinthalapally V Rao
Nov 1, 2011·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Marina Pacheco, Torsten O Nielsen
Jun 8, 2013·ILAR Journal·Shama ViraniLaura S Rozek
Sep 27, 2013·Journal of Molecular Cell Biology·Simona CitroSusanna Chiocca
Jul 18, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L R MolifeJ S de Bono
May 25, 2012·Expert Opinion on Therapeutic Targets·Syed F ZafarBassel El-Rayes
Jan 12, 2016·Expert Review of Molecular Diagnostics·Fei Ma, Chun-yang Zhang
Sep 14, 2014·Expert Opinion on Investigational Drugs·Jason TasoulasStamatios Theocharis
Nov 4, 2011·Expert Opinion on Investigational Drugs·L Rhoda Molife, Johann S de Bono
Oct 29, 2010·Journal of Biomedicine & Biotechnology·Abhinav SidanaRonald Rodriguez
Jan 6, 2016·Hormones & Cancer·Christopher Foley, Nicholas Mitsiades
Dec 9, 2014·Epigenetics : Official Journal of the DNA Methylation Society·Sridurga MithraprabhuAndrew Spencer

❮ Previous
Next ❯

Software Mentioned

SPSS
GraphPad Prism

Related Concepts

Related Feeds

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.